The gradual titration schedule serves multiple clinical purposes
Enzo Spisni, [email protected] These authors have contributed equally to this work $ These authors have contributed equally to this work and share last authorship ORCID: Fabio Vivarelli, orcid.org/0000-0002-8734-0985 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
202201011395 to X.L
They follow Good Manufacturing Practices
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda) follow gradual dose-escalation protocols to minimize side effects while achieving therapeutic goals
21% Average weight loss at 12 months: Members combining GLP-1 medications with support from WW Med+ 1 29.1% More weight loss: Members who engaged regularly with the GLP-1 Success Program at 12 months 2 87% Blood pressure change: Members prescribed weight loss medications through WW Med+ who had high blood pressure when starting, had normal blood pressure after 12 months 3 0.75 Decrease in HbA1c at six months: Members participating in the Weight Watchers Diabetes Program 4 Our consultative approach fits your priorities Our focus is on helping you define the right weight management strategy to solve your biggest weight health challenges